+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 65Years
All Genders
Healthy Volunteers
ID07430397

Evaluating Safety and Effects of CITY-FXI, a Subcutaneous siRNA, in Adults with Factor V Leiden, Prothrombin G20210A Mutation, or History of Venous Thromboembolism

Led by City Therapeutics · Updated on 2026-09-25

182

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating CITY-FXI, a small interfering RNA siRNA drug, in healthy adults and adults with Factor V Leiden FVL, prothrombin G20210A mutation, or a history of provoked venous thromboembolism VTE. This first-in-human, randomized, double-blind, placebo-controlled study aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of CITY-FXI. The study is conducted in three parts to evaluate single and multiple doses across different participant groups. The trial includes three parts Part A tests single ascending doses in healthy adults Part B tests single ascending doses in adults with FVL or prothrombin G20210A mutation Part C evaluates multiple doses in adults with these mutations andor a history of provoked VTE. CITY-FXI and placebo are given by subcutaneous injection. Different dosing schedules apply for each part to assess how the drug behaves and is tolerated. Participants will undergo genetic testing confirmation when applicable and are monitored for adverse events up to 360 days. Pharmacokinetic measures include plasma concentration and urine excretion of CITY-FXI, while pharmacodynamics involve monitoring Factor XI levels, its activity, and blood clotting times. Safety, tolerability, and detailed laboratory assessments take place during and after dosing, with follow-up extending to one year after treatment initiation.

CONDITIONS

Brief Title

A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults, Adults With FV Leiden or Prothrombin G20210A Mutation, and Adults With a History of Provoked Venous Thromboembolism

Research Team

C

City Therapeutics

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here